P0701: Trans-continental analysis of determinants of response to COVID-19 vaccination in 2268 patients with Inflammatory Bowel DiseaseECCO'25Year: 2025
Authors: Wong, S.Y.(1)*;Moran, H.R.(1);Rajauria, P.(1);Giselbrecht, E.(1);Wellens, J.(2);Vermiere, S.(2);Watanabe, K.(3);Kamikozuru, K.(4);Halfvarson, J.(5);Bergemalm, D.(5);Silverberg, M.S.(6);Ng, S.C.(7);Mak, J.W.Y.(8);Ahuja, V.(9);Virmani, S.(9);Kedia, S.(9);Lindsay, J.O.(10);Abreu, M.T.(11);Allez, M.(12);Rubin, D.T.(13);Dutta, U.(14);Sinha, S.K.(14);Sharma, V.(14);Samanta, J.(14);Shah, J.(14);Singh, A.K.(14);Kaur, H.(14);Kaplan, G.(15);Thompson, C.(16);Colombel, J.F.(1);Satsangi, J.(17);
(1)Icahn School of Medicine at Mount Sinai, Henry D. Janowitz Division of Gastroenterology, New York, United States;(2)Leuven University Hospitals, Department of Gastroenterology and Hepatology, Leuven, Belgium;(3)Toyama University, Department of Internal Medicine for Inflammatory Bowel Disease, Toyama, Japan;(4)Hyogo Medical University, Division of Gastroenterology and Hepatology Department of Internal Medicine, Hyogo, Japan;(5)Faculty of Medicine and Health- Örebro University, Department of Gastroenterology, Örebro, Sweden;(6)Mount Sinai Hospital- University of Toronto, Division of Gastroenterology- Department of Medicine, Toronto, Canada;(7)The Chinese University of Hong Kong, Microbiota I-Center- Department of Medicine and Therapeutics, Hong Kong, China;(8)The Chinese University of Hong Kong, Department of Medicine and Therapeutics, Hong Kong, China;(9)All India Institute of Medical Sciences, Department of Gastroenterology, New Delhi, India;(10)Queen Mary University of London - Barts Health NHS Trust, Center for Immunobiology- Blizard Institute, London, United Kingdom;(11)University of Miami- Miller School of Medicine, Crohn’s and Colitis Center, Miami, United States;(12)APHP- Université Paris Cité, Hopital Saint-Louis, Paris, France;(13)University of Chicago Medicine, Inflammatory Bowel Disease Center, Chicago, United States;(14)Postgraduate Institute of Medical Education and Research, Department of Gastroenterology, Chandigarh, India;(15)Inflammatory Bowel Disease Clinic- University of Calgary, Division of Gastroenterology- Department of Medicine, Calgary, Canada;(16)Warwick Medical School- University of Warwick, Division of Biomedical Sciences, Warwick, United Kingdom;(17)University of Oxford, Translational Gastroenterology Unit- Nuffield Department of Medicine, Oxford, United Kingdom;
(1) Wong SY, Wellens J, Helmus D, et al. Geography Influences Susceptibility to SARS-CoV-2 Serological Response in Patients With Inflammatory Bowel Disease: Multinational Analysis From the ICARUS-IBD Consortium. Inflamm Bowel Dis. 2023;29(11):1693-1705. doi:10.1093/ibd/izad097
(2) Goodyear CS, Patel A, Barnes E, et al. Immunogenicity of third dose COVID-19 vaccine strategies in patients who are immunocompromised with suboptimal immunity following two doses (OCTAVE-DUO): an open-label, multicentre, randomised, controlled, phase 3 trial. Lancet Rheumatol. 2024;6(6):e339-e351. doi:10.1016/S2665-9913(24)00065-1
(3) Barnes E, Goodyear CS, Willicombe M, et al. SARS-CoV-2-specific immune responses and clinical outcomes after COVID-19 vaccination in patients with immune-suppressive disease. Nat Med. 2023;29(7):1760-1774. doi:10.1038/s41591-023-02414-4
P0702: Efficacy of subcutaneous infliximab maintenance therapy according to disease location in patients with moderate-to-severe Crohn’s disease: A post hoc analysis of the Phase 3 LIBERTY-CD studyECCO'25Year: 2025
Authors: Schreiber, S.W.(1)*;Colombel, J.F.(2);Dubinsky, M.C.(3);Sands, B.E.(2);Abraham, B.P.(4);Regueiro, M.(5);Danese, S.(6);Park, H.(7);Kim, D.H.(7);Lee, Y.N.(7);Hanauer, S.B.(8);
(1)University Hospital Schleswig-Holstein, Department of Medicine I, Kiel, Germany;(2)Icahn School of Medicine at Mount Sinai, Dr. Henry D. Janowitz Division of Gastroenterology, New York NY, United States;(3)Icahn School of Medicine at Mount Sinai, Department of Pediatrics- Susan and Leonard Feinstein Inflammatory Bowel Disease Clinical Center, New York NY, United States;(4)Houston Methodist Hospital, Division of Gastroenterology and Hepatology- Department of Medicine- Lynda K. and David M. Underwood Center for Digestive Disorders, Houston TX, United States;(5)Cleveland Clinic Lerner College of Medicine of Case Western Reserve University, Department of Medicine, Cleveland OH, United States;(6)IRCCS San Raffaele Hospital and Vita-Salute University, Department of Gastroenterology, Milan, Italy;(7)Celltrion- Inc., Global Medical Division, Incheon, Korea- Republic Of;(8)Northwestern University- Feinberg School of Medicine, Division of Gastroenterology and Hepatology- Department of Medicine, Chicago IL, United States;
1. Dulai PS, et al. Clin Gastroenterol Hepatol. 2019;17(13):2634-2643.
2. Hanauer SB, et al. Gastroenterology. 2024;167(5):919-933.
P0704: A Multicenter Study Evaluating the Persistence, Effectiveness, and Safety of Methotrexate in Patients with Inflammatory Bowel Disease: The MICI-METHO StudyECCO'25Year: 2025
Authors: Caron, B.(1)*;Kirchgesner, J.(2);Nachury, M.(3);Bouguen, G.(4);Uzzan, M.(5);Buisson, A.(6);Le Cosquer, G.(7);Vuitton, L.(8);Seksik, P.(2);Petit, S.(9);Wils, P.(3);Nancey, S.(10);Altwegg, R.(11);Hupe, M.(12);Fumery, M.(13);Roblin, X.(14);Laharie, D.(15);Hebuterne, X.(16);Baumann, C.(17);Vicaut, E.(18);Peyrin-Biroulet, L.(1);
(1)Nancy University Hospital, Gastroenterology, Vandoeuvre-lès-Nancy, France;(2)Saint Antoine Hospital, Gastroenterology, Paris, France;(3)Lille University Hospital, Gastroenterology, Lille, France;(4)Rennes University Hospital, Gastroenterology, Rennes, France;(5)Henri Mondor Hospital, Gastroenterology, Paris, France;(6)Clermont-Ferrand University Hospital, Gastroenterology, Clermont-Ferrand, France;(7)Toulouse University Hospital, Gastroenterology, Toulouse, France;(8)Besançon University Hospital, Gastroenterology, Besançon, France;(9)Nancy University Hospital, Infiny Institute, Vandoeuvre-lès-Nancy, France;(10)Lyon University Hospital, Gastroenterology, Lyon, France;(11)Montpellier University Hospital, Gastroenterology, Montpellier, France;(12)Grenoble University Hospital, Gastroenterology, Grenoble, France;(13)Amiens University Hospital, Gastroenterology, Amiens, France;(14)Saint Etienne University Hospital, Gastroenterology, Saint Etienne, France;(15)Bordeaux University Hospital, Gastroenterology, Bordeaux, France;(16)Nice University Hospital, Gastroenterology, Nice, France;(17)Nancy University Hospital, Methodology- data management and statistic, Vandoeuvre-lès-Nancy, France;(18)Lariboisière Hospital, Clinical Trial Unit, Paris, France;
P0705: Features of optimal disease control in Crohn’s disease and Ulcerative Colitis: Views on IBD Expectations and Well-being by Patients and Treatment providersECCO'25Year: 2025
Authors: Rubin , D.T.(1);Potts Bleakman , A.(2)*;Orleck , K.(3);Hibi , T.(4);Bernstein , M.(5);Kearns , K.(6);Patel , A.(7);Folian , S.(8);Kayhan , C.(2);Baygani , S.(9);Flynn , E.(10);Favia , A.(11);Knight , H.(12);Castellano , G.(13);Schreiber , S.(14);
(1)University of Chicago, Medicine Inflammatory Bowel Disease Center, Chicago, United States;(2)Eli Lilly and Company, Medical Affairs, Indianapolis, United States;(3)Atlanta Gastroenterology Associates, United Digestive, Atlanta, United States;(4)Kitasato University, Kitasato Institute Hospital, Tokyo, Japan;(5)Florida Digestive Health Specialists, Gastroenterology Associates of Sarasota, Sarasota, United States;(6)Duly Health and Care, Gastroenterology, Hoffman Estates, United States;(7)SAIA South Asian IBD Alliance, Patient Advocacy, East Dundee, United States;(8)Eli Lilly and Company, Value- Evidence- and Outcomes, Indianapolis, United States;(9)Eli Lilly and Company, Statistics, Indianapolis, United States;(10)Eli Lilly and Company, Scientific Communications, Indianapolis, United States;(11)Eli Lilly and Company, Corporate Business Development, Indianapolis, United States;(12)Adelphi Real World, Autoimmune Franchise, Bollington, United Kingdom;(13)Adelphi Real World, Statistics and Data Analytics, Bollington, United Kingdom;(14)University Hospital Schleswig-Holstein, Institute of Clinical Molecular Biology- Clinic for Internal Medicine, Kiel, Germany;
P0706: Dose intensification of subcutaneous vedolizumab is an effective and safe option in Inflammatory Bowel Disease patients: Results from the multicentre OPTI-VEDO studyECCO'25Year: 2025
Authors: Wils, P.(1)*;Altwegg, R.(2);Buisson, A.(3);Vuitton, L.(4);Nancey, S.(5);Richard, N.(6);Fumery, M.(7);Bouguen, G.(8);Guillo, L.(9);Caron, B.(10);Duveau, N.(11);Stefanescu, C.(12);Pelletier, A.L.(13);Reenaers, C.(14);Gilletta, C.(15);Uzzan, M.(16);Arab, N.(17);Laharie, D.(18);Vidon, M.(19);Amiot, A.(20);Le berre, C.(21);Kirchgesner, J.(22);Dewit, O.(23);Simon, M.(24);Goutorbe, F.(25);Vicaut, E.(26);Peyrin-Biroulet, L.(10);
(1)Lille University Hospital, Gastroenterology department, Lille, France;(2)Montpellier University Hospital, Gastroenterology department, Montpellier, France;(3)Clemont Ferrand University Hospital, Gastroenterology, Clermont Ferrand, France;(4)Besançon University Hospital, Gastroenterology, Besançon, France;(5)Lyon University Hospital, Gastroenterology, Lyon, France;(6)Rouen University Hospital, Gastroenterology, Rouen, France;(7)Amiens University Hospital, Gastroenterology, Amiens, France;(8)Rennes University Hospital, Gastroenterology, Rennes, France;(9)Marseille University Hospital, Gastroenterology, Marseille, France;(10)Nancy University Hospital, Gastroenterology, Nancy, France;(11)Roubaix Hospital, Gastroenterology, Roubaix, France;(12)institut des mici, Gastroenterology, Paris, France;(13)Bichat, Gastroenterology, Paris, France;(14)Liege Hospital, Gastroenterology, Liège, Belgium;(15)Toulouse University Hospital, Gastroenterology, Toulouse, France;(16)Henri Mondor Hospital, Gastroenterology, Créteil, France;(17)Nice University Hospital, Gastroenterology, Nice, France;(18)Bordeaux University Hospital, Gastroenterology, Bordeaux, France;(19)Henri Mondor, Gastroenterology, Créteil, France;(20)Kremlin-Bicètre, Gastroenterology, Paris, France;(21)Nantes University Hospital, Gastroenterology, Nantes, France;(22)Saint Antoine AP-HP, Gastroenterology, Paris, France;(23)Louvain, Gastroenterology, Louvain, Belgium;(24)IMM, Gastroenterology, Paris, France;(25)Bayonne Hospital, Gastroenterology, Bayonne, France;(26)AP-HP, Clinical research, Paris, France; GETAID group
P0707: Impact of age of disease diagnosis on disease phenotype and severity in patients with Inflammatory Bowel DiseasesECCO'25Year: 2025
Authors: Panayiotou, S.(1)*;Orfanoudaki, E.(1,2);Papatzelou, I.(1);Foteinogiannopoulou, K.(1);Theodoraki, E.(1);Drygiannakis, I.(1);E. Koutroubakis, I.(1);
(1)University Hospital of Heraklion, Gastroenterology Department, Heraklion- Crete, Greece;(2)General Hospital of Chania «Agios Georgios», Gastroenterology Department, Chania- Crete, Greece;
P0708: Advanced Therapies in Elderly Patients with Inflammatory Bowel Disease: A Comparative Retrospective Cohort Study in TaiwanECCO'25Year: 2025
Authors: Lin, S.H.(1)*;Chiu, H.Y.(2);Kuo, C.J.(3,4,5);Chen, C.M.(5,6);Wu, R.C.(7);Chiu, C.T.(3,4,5); Su, M.Y.(1);Chang, C.W.(8);Pan, Y.B.(9); Le, P.H.(3,4,5);
(1)New Taipei Municipal TuCheng Hospital, Division of Gastroenterology and Hepatology- Department of Internal Medicine, New Taipei city, Taiwan;(2)Chang Gung University, School of Medicine, Taoyuan City, Taiwan;(3)Chang Gung Memorial Hospital, Department of Gastroenterology and Hepatology, Linkou- Taoyuan, Taiwan;(4)Chang Gung Memorial Hospital, Microbiota Therapy Center, Linkou- Taoyuan, Taiwan;(5)Chang Gung Memorial Hospital, Inflammatory Bowel Disease Center, Linkou- Taoyuan, Taiwan;(6)Chang Gung Memorial Hospital, Department of Medical Imaging and Interventions, Linkou- Taoyuan, Taiwan;(7)Chang Gung Memorial Hospital, Department of Anatomic Pathology, Linkou- Taoyuan, Taiwan;(8)Mackay Memorial Hospital, Department of Gastroenterology and Hepatology, Taipei, Taiwan;(9)Chang Gung Memorial Hospital, Biostatistical Section- Clinical Trial Center, Linkou- Taoyuan, Taiwan;
1.Sturm A, Maaser C, Mendall M, et al. European Crohn’s and Colitis Organisation topical review on IBD in the elderly. J Crohns Colitis. 2017;11:263-273.
2.Sousaa P, Bertanib L, Rodrigues C. Management of inflammatory bowel disease in the elderly: A review. Dig Liver Dis. 2023;55(8):1001-1009.
P0709: Patient Satisfaction with Subcutaneous versus Intravenous Vedolizumab: A Prospective Observational StudyECCO'25Year: 2025
Authors: Herrera De Guise, C.M.(1)*;Serra-Ruiz, X.(1);Céspedes Martínez, E.(1);Mayorga Ayala, L.(1);Robles Alonso, V.(1);Lastiri Gonzalez, E.(1);Oller, E.(1);Pérez Martínez, Z.(1);Casellas, F.(1);Borruel Sainz, N.(1);
(1)Unitat d’Atenció Crohn-Colitis- Hospital Universitari Vall d’Hebron, Gastroenterology, Barcelona, Spain;
P0710: Effectiveness and Safety of Filgotinib After One Year in Patients with Ulcerative Colitis: Preliminary Results from the Filguito Registry in Andalusia (Spain)ECCO'25Year: 2025
Authors: Caballero Mateos, A.M.(1)*;Suárez-Toribio, Á.(2);Trigo-Salado, C.(3);Rodríguez-González, F.J.(4);Silva-Albarellos, E.(5);Martín-Rodríguez, M.D.M.(6);Gijón-Villanova, R.(7);Gómez-Delgado, E.(8);Benítez, J.M.(9);Trapero-Martínez, A.M.(10);Hernández-Martínez, Á.(11);Olmedo-Martín, R.V.(12);
(1)Santa Ana Hospital, Gastroenterology, Motril- Granada, Spain;(2)Virgen del Rocío University Hospital, Gastroenterology, Granada, Spain;(3)Virgen del Rocío University Hospital, Gastroenterology, Seville, Spain;(4)Virgen de la Victoria, Gastroenterology, Málaga, Spain;(5)Virgen Macarena University Hospital, Gastroenterology, Seville, Spain;(6)Virgen de las Nieves University Hospital, Gastroenterology, Granada, Spain;(7)San Cecilio University Hospital, Gastroenterology, Granada, Spain;(8)Juan Ramón Jiménez Hospital, Gastroenterology, Huelva, Spain;(9)Reina Sofía University Hospital, Gastroenterology, Córdoba, Spain;(10)University Hospital of Jaén, Gastroenterology, Jaén, Spain;(11)Torrecárdenas University Hospital, Gastroenterology, Almería, Spain;(12)Regional University Hospital, Gastroenterology, Málaga, Spain; GATEII
- Van Rompaey L, Galien R, van der Aar EM, et al. Preclinical characterization of GLPG0634,a selective inhibitor of JAK1, for the treatment of inflammatory diseases. J Immunol 2013;191: 3568–77.
- Danese S, Argollo M, Le Berre C, Peyrin-Biroulet L. JAK selectivity for inflammatorybowel disease treatment: does it clinically matter? Gut 2019; 68:1893–99.
-Feagan BG, Danese S, Loftus EV Jr et al. Filgotinib as induction and maintenance therapy for ulcerative colitis (SELECTION): a phase 2b/3 double- blind, randomised, placebo-controlled trial. Lancet. 2021 Jun19;397(10292):2372-2384. doi: 10.1016/S0140-6736(21)00666-8. Epub 2021Jun 3.
P0711: The Effect of Extraintestinal Manifestations Presence on Treatment Persistence in IBD TreatmentECCO'25Year: 2025
Authors: Koç, Ö.(1)*;Eroglu, Z.(1);Yılmaz, V.(1);Acehan, M.F.(1);Guvenir, S.T.(1);Toruner, M.(2);
(1)Ankara University School of Medicine, Department of Gastroenterology, Ankara, Turkey;(2)Ankara University Medical School- Ibni-sina Hospital, Department of Gastroenterology, Ankara, Turkey;
P0712: Feasibility of a smart toilet seat for the measurement of physiological parameters in active Ulcerative Colitis: A pilot study.ECCO'25Year: 2025
Authors: Hazeleger, L.(1,2)*;Verbiest, V.(3);Hamers, J.(3);Groenendaal, W.(4,5);Wentink, E.(3);Duijvestein, M.(1);
(1)Radboud University Medical Center, Gastroenterology and Hepatology, Nijmegen, The Netherlands;(2)Radboudumc within OnePlanet Research Center, Precision Health- Nutrition & Behavior Group, Wageningen, The Netherlands;(3)imec within OnePlanet Research Center, Precision Health- Nutrition & Behavior Group, Wageningen, The Netherlands;(4)Stichting Imec the Netherlands, Not applicable, Eindhoven, The Netherlands;(5)OnePlanet Research Center, Not applicable, Wageningen, The Netherlands;
P0713: Feasibility of a Physical Activity intervention in Patients with IBD - the PASIBO StudyECCO'25Year: 2025
Authors: Poulsen, A.(1)*;Thomsen, T.(2,3); Villumsen, M.(2);Søe Riis Jespersen, H.(4);Blædel Hansen, A.(2);Appel Esbensen, B.(5,6);Jess, T.(7);Højgaard Allin, K.(7);Aadahl, M.(2,6);
(1)University Hospital of Copenhagen- Rigshospitalet, Department of Digestive Diseases- Transplantation- and General Surgery- Section for IBD, Copenhagen, Denmark;(2)University Hospital of Copenhagen- Frederiksberg, Center for Clinical Research and Prevention, Copenhagen, Denmark;(3)University Hospital of Copenhagen- Rigshospitalet- Glostrup, Center for Rheumatology and Spine Diseases, Copenhagen, Denmark;(4)University Hospital of Copenhagen- Bispebjerg, Digestive Disease Center, Copenhagen, Denmark;(5)University Hospital of Copenhagen- Rigshospitalet Glostrup, Center for Rheumatology and Spine Diseases, Copenhagen, Denmark;(6)University of Copenhagen, Department of Clinical Medicine- Faculty of Health Science, Copenhagen, Denmark;(7)Aalborg University, Center for Molecular Prediction of Inflammatory Bowel Disease PREDICT, Aalborg, Denmark;
P0714: Low risk of recurrent or new neoplasia after immunomodulatory therapy in patients with Inflammatory Bowel Disease and previous cancer: a multicentre retrospective Italian studyECCO'25Year: 2025
Authors: Mancone, R.(1);Neri, B.(1)*;Bonacci, L.(2);Fiorillo, M.(1);Schiavone, S.C.(1);Sparacino, A.(3);Testa , A.(2);Festa , S.(4);Marafini, I.(1);Orlando, A.(3);Castiglione, F.(5);Fries, W.(6);Calabrese, E.(1);Monteleone, G.(1);Biancone, L.(1);
(1)University of Rome Tor Vergata, Systems Medicine, Roma, Italy;(2)University of Naples Federico II, Clinical Medicine and Surgery, Naples, Italy;(3)University of Palermo, Internal Medicine, Palermo, Italy;(4)Ospedale San Filippo Neri, IBD-Unit, Roma, Italy;(5)University of Naples Federico II, Cinical Medicine and Surgery, Naples, Italy;(6)University of Messina, Clinical Medicine, Messina, Italy;
1. Gordon H. et al. ECCO Guidelines on IBD and Malignancies, Journal of Crohn's and Colitis, 2023.
P0715: Experience with Ustekinumab and Vedolizumab in Inflammatory Bowel Disease Patients: Single-Center DataECCO'25Year: 2025
Authors: Kandemir, H.(1)*;Karataş, A.(1);Moral, K.(1);Bilican, G.(1);Kekilli, M.(1);Cindoruk, M.(1);Karakan, T.(1);
(1)Gazi Univercity, Gastroenterology, Ankara, Turkey;
P0716: Comparison of vedolizumab and ustekinumab treatment persistence in anti-TNF experienced perianal Crohn's Disease patients: A Single Center ExperienceECCO'25Year: 2025
Authors: Eroglu, Z.(1);Acehan, M.F.(1);Koç, Ö.(1)*;Yılmaz, V.(1);Toruner, M.(2);
(1)Ankara University School of Medicine, Department of Gastroenterology, Ankara, Turkey;(2)Ankara University Medical School- Ibni-sina Hospital, Department of Gastroenterology, Ankara, Turkey;
P0718: Ulcerative Proctitis: Adherence to Guidelines and confirmation of clinical, biochemical and endoscopic remission in phenotypically E1 patients.ECCO'25Year: 2025
Authors: Malkopoulos, A.(1)*;Gluch, A.(2);Kakkadasam Ramaswamy , P.(1);Mohsen , W.(1);
(1)Gold Coast University Hospital, Gastroenterology, Gold Coast, Australia;(2)Griffith University, School of Medicine, Gold Coast, Australia;
P0719: The SAPHIR study: Assessment of Fresenius Kabi adalimumab biosimilar persistence in patients with inflammatory chronic diseases: Descriptive analysis of patients baseline characteristicsECCO'25Year: 2025
Authors: Peyrin-Biroulet , L.(1)*;Bouguen , G.(2);Becheur , H.(3);Cambon , A.(4);Bouhnik , Y.(5);
(1)Hôpital universitaire de Nancy, Département de Gastroentérologie, Vandoeuvre-lès-Nancy-, France;(2)CHU Pontchaillou et Université de Rennes 1, Service des maladies de l'appareil digestif et INSERM U991, Rennes, France;(3)Université de Paris- Hôpital Bichat- APHP-, Service de Gastroentérologie et d'oncologie digestive, Paris, France;(4)Hôpital d'Instruction des Armées HIA Sainte-Anne- Service de Santé des Armées SSA, Service de Médecine interne et d'Infectiologie-, Toulon, France;(5)Groupe Hospitalier Privé Ambroise Paré - Hartmann, Institut des MICI Institut des maladies inflammatoires chroniques de l'intestin, Neuilly-sur-Seine, France;
P0720: Cost-effectiveness of vedolizumab vs. ustekinumab as first-line biologic in treatment sequencing for ulcerative colitis in CanadaECCO'25Year: 2025
Authors: Kao, K.E.(1);Zhou, J.Y.(2)*;Mac, S.(2);Martin, M.(1);Johnston, K.(1);Marshall, J.K.(3);
(1)Broadstreet Health Economics and Outcomes Research, Broadstreet Health Economics and Outcomes Research, Vancouver, Canada;(2)Takeda Canada Inc., Patient Value and Access, Toronto, Canada;(3)McMaster University, Department of Medicine Division of Gastroenterology and Farncombe Family Digestive Health Research Institute-, Hamilton, Canada;
1. Jiang J, Wojtowicz AM, Sanni O, Uyei J, Jin H, Lindsley K, et al. S1149 Comparative Efficacy and Safety of Subcutaneous Vedolizumab versus Other Targeted Inflammatory Bowel Disease Therapies in Patients With Moderate to Severe Ulcerative Colitis: A Network Meta-Analysis. Official journal of the American College of Gastroenterology | ACG. 2024 Oct;119(10S):S816.
2. Das R, Steinhart AH. Choosing Therapies in Ulcerative Colitis. Journal of the Canadian Association of Gastroenterology. 2023;7(1):9-21.
3. Lu X, Jarrett J, Sadler S, Tan M, Dennis J, Jairath V. Comparative efficacy of advanced treatments in biologic-naïve or biologic-experienced patients with ulcerative colitis: a systematic review and network meta-analysis. Int J Clin Pharm. 2023;45(2):330-341.
